GlassScriptPhysician profile
Alan L Elliott
NPI 1811936107
$19,176.82
in general payments reported to CMS, 2019-2025
32 companies · $2,632 in 2025
The $2,632 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,673 · 2020: $1,983 · 2021: $2,246 · 2022: $2,986 · 2023: $3,027 · 2024: $3,630 · 2025: $2,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,100 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,099.78 |
| Education | $189.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,052.75 | 2019-2025 | |
| Amgen INC. | $2,675.68 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $1,874.86 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $1,391.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,256.96 | 2019-2025 | |
| Ucb, INC. | $1,159.59 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $1,025.85 | 2019-2024 | Taltz, Zepbound |
| Horizon Therapeutics Plc | $708.24 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $698.47 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $641.36 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $457.08 | 2021-2025 | Saphnelo |
| Genentech USA, INC. | $397.95 | 2019-2025 | Actemra, Gazyva |
| Mallinckrodt Hospital Products INC. | $339.54 | 2020-2025 | Acthar |
| Radius Health, INC. | $313.43 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $308.38 | 2021-2025 | Lupkynis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $268.79 | 2023-2025 | Hyrimoz |
| Fresenius Kabi USA, LLC | $182.20 | 2023-2024 | Idacio |
| Sobi, INC | $167.06 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $160.02 | 2019-2020 | |
| Celgene Corporation | $159.42 | 2019 | |
| Ani Pharmaceuticals, INC. | $153.62 | 2023 | Purified Cortrophin Gel |
| Pacira Therapeutics, INC. | $134.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.55 | 2023-2025 | Ofev, Cyltezo |
| Alexion Pharmaceuticals, INC. | $106.41 | 2019-2024 | Strensiq |
| Genzyme Corporation | $99.06 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $90.52 | 2023-2024 | Uptravi, Opsumit |
| Organon LLC | $89.40 | 2023-2025 | Renflexis, Hadlima |
| Celltrion USA INC. | $35.38 | 2023 | Yuflyma |
| Mallinckrodt Enterprises LLC | $28.78 | 2019 | |
| Hikma Pharmaceuticals USA | $28.67 | 2019-2023 | Mitigare |
| Teva Pharmaceuticals USA, INC. | $27.92 | 2023-2024 | Truxima, Simlandi |
| Scilex Pharmaceuticals INC. | $18.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.